Catalog No.
Product Name
Application
Product Information
Citations
-
Neuraminidase Inhibitor
Neuraminidase-IN-8 is a potent inhibitor of neuraminidase, demonstrating an IC50 of 0.027 µM. This compound exhibits significant anti-influenza activity, making it a valuable tool for research into antiviral therapies targeting influenza virus replication and spread. Its effectiveness in inhibiting neuraminidase enzymes supports its use in studies aimed at developing new strategies for influenza treatment. -
Neuraminidase Inhibitor
Neuraminidase-IN-11 is a highly potent and selective inhibitor of neuraminidase with IC50 values of 4.7 nM, 8.46 nM, and 1.5 nM against H1N1, H5N1, and H5N8 neuraminidases, respectively. This compound plays a crucial role in the study of viral pathogenesis and therapeutic interventions for influenza. Its selective inhibition of neuraminidase makes it an important tool for understanding antiviral drug efficacy and the modulation of viral replication dynamics. -
Anti-H1N1 Agent
Wulignan A1 is an isolated compound from the stems of Schisandra henryi, primarily targeting the influenza virus. It demonstrates significant anti-H1N1 activity, including efficacy against the H1N1-TR strain, which is resistant to Tamiflu. This compound is valuable for research focused on antiviral therapies and the development of new treatments for influenza infections. -
Influenza Virus Hemagglutinin Epitope
Influenza HA (518-526) is an H-2Kd-restricted peptide epitope derived from the hemagglutinin protein of the influenza virus, specifically composed of amino acids 518 to 526. This epitope plays a crucial role in immune recognition and response, making it valuable for research on influenza pathogenesis and vaccine development. Applications include T cell studies, epitope mapping, and the generation of immunological assays to investigate the immune response to influenza infections. -
Influenza Virus Inhibitor
Antiviral agent 35 is a potent inhibitor of influenza virus replication, functioning effectively during the early stages of the viral life cycle. It reduces reactive oxygen species (ROS) accumulation, as well as autophagy and apoptosis induced by the virus, while also mitigating the inflammatory response mediated by the RIG-1 pathway in mouse models of pulmonary infection. This compound exhibits low cytotoxicity, with a CC50 greater than 800 μM in MDCK cells, and demonstrates anti-H1N1 activity with an EC50 of 2.28 μM, making it a valuable tool for research on influenza virus inhibition. -
Influenza A Virus Inhibitor
Influenza A virus-IN-18 (Compound C2e) is an orally active inhibitor specifically targeting the Influenza A virus. It demonstrates significant antiviral activity, with an IC50 value of 2.5 μM against PR8/H1N1 and 6.42 μM against H3N2 strains. Influenza A virus-IN-18 exhibits a high affinity for the H1N1/PR8 hemagglutinin protein, with a KD of 0.25 μM. This compound is valuable for research in Influenza A virus infection and therapeutic development. -
Anti-influenza Virus Agent
Laninamivir octanoate hydrate is a prodrug of Laninamivir, functioning primarily as a long-acting neuraminidase inhibitor. It exhibits potent anti-influenza virus activity, demonstrating efficacy against strains resistant to Oseltamivir as well as pandemic influenza viruses. This compound is valuable for research focused on antiviral drug development and the study of influenza virus resistance mechanisms. -
H5N1 Inhibitor
Yadanziolide B is a natural quassinoid that functions as an inhibitor of H5N1 neuraminidase, an essential enzyme for the viral life cycle. Its inhibitory activity makes it a valuable candidate for research applications focusing on antiviral therapies targeting H5N1 influenza. Studies exploring its properties may contribute to the development of effective treatments for influenza virus infections. -
RdRP Inhibitor
RdRP-IN-5 is a potent inhibitor of influenza virus RNA-dependent RNA polymerase (RdRP). This compound exhibits significant antiviral activity, making it a valuable tool for the study of influenza virus replication and pathogenesis. Researchers can utilize RdRP-IN-5 to investigate therapeutic strategies targeting RNA polymerase in viral infections. -
Antiviral Agent
Caprochlorone is an antiviral agent primarily targeting orthopoxvirus. It inhibits viral cell penetration and delays the release of newly formed virions from infected cells. In preclinical studies, Caprochlorone has demonstrated efficacy by significantly reducing influenza virus titers in the lungs of infected mice, highlighting its potential for further antiviral research applications. -
Anti-Influenza Agent
Anti-Influenza Agent 4 is a selective inhibitor of the influenza virus, demonstrating effective antiviral activity with EC50 values of 150 nM and 62 nM against the A/Roma and A/Parma strains, respectively. This compound is valuable for researchers studying influenza virus mechanisms and developing therapeutic interventions. Its potency makes it a significant tool for exploring antiviral strategies in clinical and laboratory settings. -
Influenza Viru Inhibitor
NSC-65847 is a dual inhibitor that targets both viral neuraminidase and Streptococcus pneumoniae neuraminidase, disrupting essential enzymatic functions. Its unique mechanism of action impedes the replication and spread of Influenza viruses, making it a valuable tool in antiviral research. Research applications include studying viral infections and developing therapeutic interventions for influenza and associated bacterial co-infections. -
Influenza A Virus Inhibitor
Influenza virus-IN-1 is a potent inhibitor of Influenza A virus, exhibiting an EC50 of 2.46 µM and a CC50 exceeding 200 µM. This compound demonstrates concentration-dependent inhibition of the PAN endonuclease, with an EC50 of 312.36 nM. Influenza virus-IN-1 is valuable for research focused on evaluating anti-influenza A virus therapies and elucidating viral mechanisms. -
Neuraminidase Inhibitor
Neuraminidase-IN-5 is a potent neuraminidase inhibitor, demonstrating an IC50 of 0.02 μM. Targeting the neuraminidase enzyme makes this compound a promising candidate for the development of novel anti-influenza therapies. As a dihydrofurocoumarin derivative, Neuraminidase-IN-5 offers significant potential for research applications in virology and antiviral drug discovery. -
Influenza Virus Inhibitor
Influenza virus-IN-4 is a potent inhibitor of the influenza virus neuraminidase, exhibiting IC50 values of 3.4 µM, 0.094 µM, 0.79 µM, and 0.077 µM against H5N1, H5N2, H5N6, and H5N8, respectively. This compound demonstrates effective NA-inhibitory activity, contributing to its role in antiviral research. Additionally, Influenza virus-IN-4 exhibits low cytotoxicity, with a CC50 greater than 200 µM, and displays no significant toxicity at doses of 1500 mg/kg in murine models. Its safety profile and efficacy in inhibiting neuraminidase make it a valuable tool for studying influenza virus pathogenesis and developing therapeutic strategies. -
CEN Inhibitor
Cap-dependent endonuclease-IN-8 is a potent inhibitor of cap-dependent endonuclease (CEN), a crucial enzyme in the replication of orthomyxoviruses. This compound effectively demonstrates antiviral activity against diverse strains, including influenza A, B, and C. It serves as a valuable tool for research investigating the molecular mechanisms of viral replication and the development of novel antiviral therapies. -
Neuraminidase Inhibitor
Neuraminidase-IN-6 is a potent inhibitor of neuraminidase, exhibiting an IC50 of 0.11 μM. As a 1,3,4-triazole-3-acetamide derivative, it demonstrates effective inhibition of viral neuraminidase, an essential target for anti-influenza drug development. This compound is valuable for research focused on influenza virus mechanisms and potential therapeutic strategies. -
Influenza A Viruses Inhibitor
Antiviral agent 43 is a potent entry inhibitor targeting influenza A viruses. This compound effectively inhibits the replication of various influenza A strains, including VH04-H5N1 and PR8-H1N1, with EC50 values of 240 nM and 72 nM, respectively. Its oral bioavailability makes it a valuable tool for research into antiviral therapies against influenza A virus infections. -
CEN Inhibitor
Sebaloxavir marboxil is a potent inhibitor of cap-dependent endonuclease (CEN). This compound effectively suppresses the replication of influenza viruses, making it a valuable tool in the investigation of viral infections associated with these pathogens. Its mechanism of action highlights its potential applications in antiviral research and the development of therapeutic strategies against influenza. -
Neuraminidase Inhibitor
Massarilactone H is a polyketide that acts as a neuraminidase inhibitor, exhibiting an IC50 value of 8.18 µM. This compound demonstrates significant biological activity in modulating viral replication and has potential research applications in virology and therapeutic development against influenza and other neuraminidase-dependent pathogens. -
Influenza Virus Hemagglutinin
Influenza HA (110-119) is a peptide fragment derived from the hemagglutinin protein of the influenza virus. It specifically targets and stimulates the proliferation of regulatory T cells (Treg), playing a crucial role in modulating immune responses. This reagent is valuable for research applications in vaccine development and the study of immune regulation in response to influenza infections. -
NS1 inhibitor
NS1-IN-1 is a potent inhibitor of the NS1 protein, a critical virulence factor for the influenza A virus that disrupts host gene expression. By targeting the NS1 protein, NS1-IN-1 effectively reduces viral protein levels and inhibits virus replication. Its antiviral activity is mediated through the repression of mTORC1 signaling in a TSC1-TSC2-dependent manner, making it a valuable tool for research into influenza virus pathogenesis and potential therapeutic strategies. -
Anti-influenza Virus Compound
Spiroamantadine is an anti-influenza virus compound that demonstrates antiviral activity by inhibiting the M2 proton channel of influenza A viruses. This compound is structurally related to Amantadine and is utilized in research focused on the mechanisms of influenza virus entry and replication. It serves as a valuable tool for studies investigating antiviral strategies and the development of new therapeutic agents against influenza viruses. -
Neuraminidase Inhibitor
Neuraminidase-IN-18 is a potent neuraminidase inhibitor designed to target the neuraminidase enzyme in influenza viruses. It exhibits significant inhibitory activity against H5N1 neuraminidase, with IC50 values of 0.14 μM for the wild-type strain and 0.27 μM for the H5N1-H274Y mutant. This compound effectively inhibits influenza virus replication at the cellular level, making it a valuable tool for research in antiviral drug development and the study of influenza pathogenicity. -
CEN Inhibitor
Cap-dependent endonuclease-IN-25 is a potent inhibitor of cap-dependent endonuclease (CEN), a critical enzyme involved in viral RNA synthesis. As a macrocyclic pyridotriazine derivative, it exhibits significant potential for research focused on viral infections, particularly those caused by the Orthomyxoviridae family, including influenza viruses. This compound serves as a valuable tool in studying the mechanisms of viral replication and may aid in the development of antiviral therapeutics. -
Endonuclease Inhibitor
Suraxavir marboxil is an endonuclease inhibitor specifically targeting the PA subunit of cap-dependent endonucleases, demonstrating significant antiviral activity against influenza A and B viruses. By inhibiting the PA subunit, Suraxavir marboxil effectively disrupts viral replication. This reagent can be utilized in research to explore therapeutic strategies for preventing influenza A and B infections, both as a standalone treatment and in combination with other antiviral agents. -
Influenza Viru
Influenza NP (147-155) is a key epitope derived from the nucleoprotein of the influenza virus, specifically recognized by the immune system. This peptide plays a crucial role in studying immune responses and vaccine development against influenza. Research applications include T cell epitope mapping and the evaluation of immunogenicity in various models of influenza infection. -
Antivirus Agent
Oleoside dimethylester is a secoiridoid glucoside derived from the fruits of Ligustrum lucidum. This compound demonstrates significant antiviral activity, specifically inhibiting type 3 parainfluenza virus (Para 3) and respiratory syncytial virus (RSV) with IC50 values of 20.8 and 83.2 μg/mL, respectively. Additionally, oleoside dimethylester exhibits antioxidant properties, making it a valuable reagent for research in virology and oxidative stress studies. -
Influenza Virus Inhibitor
Influenza virus-IN-8 is a potent inhibitor targeting the influenza virus by inducing the aggregation of viral nucleoprotein (NP) and blocking its nuclear accumulation. This compound demonstrates broad-spectrum anti-influenza activity, effectively inhibiting both the replication and transcription of influenza A viruses. Additionally, Influenza virus-IN-8 is effective against Oseltamivir-resistant H1N1/pdm09 strains, making it a valuable tool for research in combating influenza virus variants. -
CEN Inhibitor
Cap-dependent endonuclease-IN-17 is a highly selective inhibitor of cap-dependent endonuclease (CEN). This compound exhibits significant antiviral activity against influenza virus A/Hanfang/359/95 (H3N2), with an IC50 value of 1.29 μM. It serves as a valuable tool for research focused on antiviral therapies and the inhibition of viral replication mechanisms. -
Anti-influenza Compounds
Neuraminidase-IN-2 is a potent antiviral compound that specifically inhibits neuraminidase, a critical enzyme for influenza virus replication. It demonstrates strong inhibitory activity against various influenza strains, exhibiting IC50 values of 0.28 µM for H1N1, 0.27 µM for 09H1N1, 11.50 µM for H3N2, 0.089 µM for H5N1, and 23.44 µM for H5N2. This compound presents a promising option for research focused on combating influenza viruses due to its effectiveness and low cytotoxicity profile. -
Polyketide
Mitorubrin is a polyketide compound isolated from Penicillium purpurogenum JS03-21. This compound has been studied for its potential biological activities; however, it exhibits no significant inhibitory effects against the H1N1 influenza virus, as indicated by an IC50 greater than 200 μM. Mitorubrin may be useful in various research applications focusing on fungal metabolites and their properties. -
Influenza Neuraminidase Inhibitor
Neuraminidase-IN-9 is a highly effective inhibitor of influenza neuraminidase, exhibiting IC50 values of 0.12 µM for H5N1, 0.049 µM for H5N2, and 0.16 µM for H5N6. This compound demonstrates significant antiviral activity, making it a valuable tool in influenza research. Neuraminidase-IN-9 can be utilized in studies aimed at understanding and combating influenza virus infections. -
CEN Inhibitor
Cap-dependent endonuclease-IN-7 is a potent inhibitor of cap-dependent endonuclease (CEN), disrupting the synthesis of viral mRNA. This inhibition subsequently hampers viral proliferation. Cap-dependent endonuclease-IN-7 is valuable for research into viral infections, including strains of influenza A, B, and C. -
Influenza Viru
M2e, human, is the extracellular peptide derived from the M2 integral membrane protein of influenza A virus. This peptide exhibits remarkable conservation across all human influenza A strains, making it a prime candidate for vaccine development. Its universal reactivity provides significant potential in research applications aimed at inducing protective immune responses against various subtypes of human influenza A. -
Anti-Influenza Agent
Anti-Influenza Agent 3 is a targeted therapeutic compound that inhibits the M2 ion channel conductivity of influenza viruses. It demonstrates potent antiviral activity with EC50 values of 3.29 µM against the A/HK/68 (H3N2, M2-WT) strain and 2.45 µM against A/WSN/33 (H1N1, M2-S31N) strain. Additionally, Anti-Influenza Agent 3 exhibits low cytotoxicity in MDCK epithelial cells, making it a promising candidate for research in influenza inhibition and antiviral drug development. -
Neuraminidase Inhibitor
DS-22-inf-021 is a neuraminidase inhibitor that exhibits antiviral activity against influenza viruses. By inhibiting neuraminidase, this compound disrupts viral replication and spread, making it a valuable tool for research in virology and antiviral drug development. Its effectiveness against influenza strains positions DS-22-inf-021 as a potential candidate for further exploration in therapeutic applications. -
Secondary Metabolite
Pulvic acid is a butenolide and a secondary metabolite derived from the marine fungus Aspergillus terreus Gwq-48. It exhibits notable antiviral activity, particularly against the influenza A H1N1 virus, with an IC50 value of 29.1 μg/mL. This compound serves as a valuable tool for researchers investigating influenza virus infections and exploring potential therapeutic strategies. -
Influenza Virus Inhibitor
Zanamivir-Cholesterol Conjugate is a long-acting neuraminidase inhibitor targeting the influenza virus. This compound exhibits potent efficacy against both drug-sensitive and drug-resistant strains of the virus, making it valuable for studying influenza pathogenesis and developing therapeutic strategies. Its unique conjugation to cholesterol enhances membrane association, potentially improving bioavailability and antiviral activity in cellular systems. -
Anti-influenza Agent
Antiviral Agent 34 is a potent and orally active compound that targets influenza A and B subtypes, exhibiting an EC50 value of 0.8 nM against H1N1 proliferation. This agent functions by inhibiting the influenza virus RNA-dependent RNA polymerase, thereby preventing viral replication. Antiviral Agent 34 is suitable for research applications focused on influenza virus mechanisms and antiviral drug development. -
Secondary Metabolite
5,6-Dihydro-6-hydroxypenicillic acid is a secondary metabolite derived from the endophytic fungus Talaromyces sp. CPCC 400783, which is associated with Reynoutria japonica Houtt. This compound exhibits antiviral activity against influenza A virus, with an IC50 value of 65.45 μM. Its unique biological properties make it a valuable reagent for research in virology and natural product studies. -
Antiviral Agent
Dihydromaniwamycin E is an antiviral agent that exhibits activity against influenza and SARS-CoV-2 viruses. This compound functions as a heat-shock metabolite, highlighting its potential in the study of viral infections and host response mechanisms. Research applications include investigating antiviral pathways and developing strategies to combat respiratory viral pathogens. -
Neuraminidase Inhibitor
4-O-Methylepisappanol is a potent neuraminidase inhibitor derived from the heartwood of Caesalpinia sappan. It effectively inhibits neuraminidase activity in various strains of influenza viruses, demonstrating IC50 values of 42.8 µM for A/Chicken/Korea/MS96/96 [H9N2] and 63.2 µM for both A/PR/8/34 [H1N1] and A/Hong Kong/8/68 [H3N2]. This compound is valuable for studying viral pathogenesis and developing antiviral therapies targeting influenza neuraminidase. -
Influenza Virus Inhibitor
Influenza virus-IN-3 is a selective inhibitor targeting the influenza virus, demonstrating potent antiviral activity with IC50 values of 0.88, 0.10, 5.5, and 0.51 µM against H5N1, H5N2, H5N6, and H5N8 strains, respectively. This compound effectively inhibits neuraminidase (NA) enzyme activity, making it a valuable tool in influenza research. With a CC50 greater than 200 µM, Influenza virus-IN-3 displays low cytotoxicity, supporting its potential use in therapeutic applications. -
Immunostimulant
Influenza A NP (383-391) (HLA-B27) is a peptide sequence that functions as an immunostimulant by targeting CD4+ T helper cells. This epitope is known to enhance the activation and proliferation of CD8+ cytotoxic T lymphocytes (CTLs), thereby promoting robust immune responses. It is applicable in research related to breast cancer and other areas of immunotherapy, facilitating the exploration of T cell-mediated responses in cancer models. -
Cholesterol-conjugated Oseltamivir Carboxylat Prodrug
OC-C2-Cholesterol is a cholesterol-conjugated prodrug of Oseltamivir carboxylate, designed to enhance oral bioavailability. This compound exhibits protective effects against influenza virus infections by providing prolonged circulation of Oseltamivir carboxylate compared to traditional formulations. OC-C2-Cholesterol serves as a valuable tool in influenza research, contributing to the understanding of antiviral efficacy and metabolism. -
CEN Inhibitor
Cap-dependent endonuclease-IN-23 is a selective inhibitor of cap-dependent endonuclease (CEN), effectively blocking its activity. This compound demonstrates significant antiviral properties by inhibiting the replication of influenza A virus. Cap-dependent endonuclease-IN-23 is intended for research applications focused on understanding and combating influenza virus infections. -
Anti-influenza Agent
ATV2301 is an orally active anti-influenza agent targeting key viral components, including polymerase acid protein (PA), nuclear protein (NP), and RNA-dependent RNA polymerase (RdRp). It exhibits potent antiviral activity, demonstrated by an EC50 of 1.88 nM against H1N1 and 4.77 nM against H3N2. ATV2301 is suitable for research applications involving the study of influenza virus replication and the development of antiviral therapeutics. -
Hemagglutinin Fragment
Hemagglutinin (48-68) is a peptide fragment derived from the hemagglutinin protein of the influenza virus. This fragment has been shown to effectively induce the proliferation of peptide-specific T-cell clones, making it valuable for research applications related to T-cell responses and adaptive immunity. It serves as a useful tool for studying the immunogenic properties of influenza virus and may aid in vaccine development and immune profiling assays. -
Anti-influenza Agent
Nepasaikosaponin K is an anti-influenza agent that exhibits potent antiviral activity against the influenza virus A/WSN/33 (H1N1). It demonstrates an EC50 value of 17.91 μM in 239T-Gluc cells, indicating its effectiveness in inhibiting viral replication. This compound is suitable for research applications focused on the development of antiviral therapies and understanding influenza virus biology.
